Search peptides, terms, sources/
Research source · 2026

Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort

About this source

Kind
Research
Design
Human clinical trial, Human observational
Population
29 treated trial participants with Bardet-Biedl syndrome compared with 58 matched registry controls
Sample size
87
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 November 2026

Limitations

The control group came from a registry, not from randomisation, so unmeasured differences between groups may remain.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.